The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
The International SNP Map Working Group, Laboratories:, C. S. H., Sachidanandam, R., Weissman, D., Schmidt, S. C., Kakol, J. M., Stein, L. D., National Center for Biotechnology Information:, Marth, G., Sherry, S., et al. (2001) · Nature · doi:10.1038/35057149 · Cited by 2,977
Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C.-M., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,886
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 1×
“…of genetic testing can indeed benefit the selection of appropriate therapeutic agent and drug dose for individual patients to improve therapeutic response, reduce adverse drug effects, and reduce overall healthcare cost are critical for wide clinical acceptance of pharmacogenetic testing.”
BackgroundHLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,835
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
A marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease
Tukey, R. H., & Strassburg, C. P. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.581 · Cited by 1,523
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Beinart, R., Goldenberg, I., Novikov, I., Pres, H., Savion, N., Varon, D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130846.46168.03 · Cited by 1,354
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H.-J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., et al. (2004) · Nature · doi:10.1038/nature02214 · Cited by 1,134
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Variability in Individual Responsiveness to Clopidogrel
Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Alfonso, F., Macaya, C., Bass, T. A., & Costa, M. A. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.11.044 · Cited by 959
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
study, F. T. D., Daly, A. K., International SAE Consortium, Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.379 · Cited by 944
Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R., & Ball, S. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000794 · Cited by 928
Wiviott, S. D., Trenk, D., Frelinger, A. L., O’Donoghue, M., Neumann, F.-J., Michelson, A. D., Angiolillo, D. J., Hod, H., Montalescot, G., Miller, D. L., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.740324 · Cited by 881
Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression
Smith, M. W., Dean, M., Carrington, M., Winkler, C., Huttley, G. A., Lomb, D. A., Goedert, J. J., O'Brien, T. R., Jacobson, L. P., Kaslow, R., et al. (1997) · Science · doi:10.1126/science.277.5328.959 · Cited by 876
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Genetic Control of Isoniazid Metabolism in Man
Evans, D. A. P., Manley, K. A., & McKusick, V. A. (1960) · BMJ · doi:10.1136/bmj.2.5197.485 · Cited by 784
Moving towards individualized medicine with pharmacogenomics
Evans, W. E., & Relling, M. V. (2004) · Nature · doi:10.1038/nature02626 · Cited by 768
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Identification of the gene for vitamin K epoxide reductase
Li, T., Chang, C.-Y., Jin, D.-Y., Lin, P.-J., Khvorova, A., & Stafford, D. W. (2004) · Nature · doi:10.1038/nature02254 · Cited by 707
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
Lee, C. R., Goldstein, J. A., & Pieper, J. A. (2002) · Pharmacogenetics · doi:10.1097/00008571-200204000-00010 · Cited by 686
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
Hung, S.-I., Chung, W.-H., Jee, S.-H., Chen, W.-C., Chang, Y.-T., Lee, W.-R., Hu, S.-L., Wu, M.-T., Chen, G.-S., Wong, T.-W., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000199500.46842.4a · Cited by 680
Translation of the Philadelphia chromosome into therapy for CML
Druker, B. J. (2008) · Blood · doi:10.1182/blood-2008-07-077958 · Cited by 668
Hesselink, D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00168-1 · Cited by 655
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W. L., Braunwald, E., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.851949 · Cited by 651
Martinelli, I., Sacchi, E., Landi, G., Taioli, E., Duca, F., & Mannucci, P. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806183382502 · Cited by 648
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Raghavan, N., Frost, C. E., Yu, Z., He, K., Zhang, H., Humphreys, W. G., Pinto, D., Chen, S., Bonacorsi, S., Wong, P. C., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023143 · Cited by 612
Pharmacogenetics and adverse drug reactions
Meyer, U. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03167-6 · Cited by 602
Poirier, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., & Gilfix, B. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.12260 · Cited by 595
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
A common polymorphism associated with antibiotic-induced cardiac arrhythmia
Sesti, F., Abbott, G. W., Wei, J., Murray, K. T., Saksena, S., Schwartz, P. J., Priori, S. G., Roden, D. M., George, A. L., & Goldstein, S. A. N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180223197 · Cited by 479
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500313 · Cited by 468
APPRAISE Steering Committee and Investigators (2009) · Circulation · doi:10.1161/circulationaha.108.832139 · Cited by 461
Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction
Chasman, D. I. (2004) · JAMA · doi:10.1001/jama.291.23.2821 · Cited by 453
Martin, A. M., Nolan, D., Gaudieri, S., Almeida, C. A., Nolan, R., James, I., Carvalho, F., Phillips, E., Christiansen, F. T., Purcell, A. W., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307067101 · Cited by 452
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
Keskitalo, J. E., Zolk, O., Fromm, M. F., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.79 · Cited by 416
SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Association of warfarin dose with genes involved in its action and metabolism
Wadelius, M., Chen, L. Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R., & Deloukas, P. (2007) · Human Genetics · doi:10.1007/s00439-006-0260-8 · Cited by 390
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury
Singer, J. B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein, L., Wright, T. M., Meyer, J., & Paulding, C. A. (2010) · Nature Genetics · doi:10.1038/ng.632 · Cited by 388
Kadakol, A., Ghosh, S. S., Sappal, B. S., Sharma, G., Chowdhury, J. R., & Chowdhury, N. R. (2000) · Human Mutation · doi:10.1002/1098-1004(200010)16:4<297::aid-humu2>3.0.co;2-z · Cited by 387
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
Thervet, E., Loriot, M. A., Barbier, S., Buchler, M., Ficheux, M., Choukroun, G., Toupance, O., Touchard, G., Alberti, C., Le Pogamp, P., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.17 · Cited by 369
Dishy, V., Sofowora, G. G., Xie, H.-G., Kim, R. B., Byrne, D. W., Stein, C. M., & Wood, A. J. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010819 · Cited by 363
NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
Kalow, W., & Staron, N. (1957) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o57-148 · Cited by 334
Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy
McLeod, H. L., & Evans, W. E. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.101 · Cited by 331
Sakaeda, T., Nakamura, T., Horinouchi, M., Kakumoto, M., Ohmoto, N., Sakai, T., Morita, Y., Tamura, T., Aoyama, N., Hirai, M., et al. (2001) · Pharmaceutical Research · doi:10.1023/a:1012244520615 · Cited by 322
Tantisira, K. G., Lake, S., Silverman, E. S., Palmer, L. J., Lazarus, R., Silverman, E. K., Liggett, S. B., Gelfand, E. W., Rosenwasser, L. J., Richter, B., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh149 · Cited by 322
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
Lamba, J. K., Lin, Y. S., Thummel, K., Daly, A., Watkins, P. B., Strom, S., Zhang, J., & Schuetz, E. G. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00006 · Cited by 316
Dahl, M. L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M., & Sjöqvist, F. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10669-1 · Cited by 313
Tang, W. K. B.-K., & Endrenyi, L. (1998) · Pharmacogenetics · doi:10.1097/00008571-199808000-00001 · Cited by 299
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
Interindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes
Lin, J. H., & Lu, A. Y. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.535 · Cited by 285
Self-citationPharmacogenomics: Challenges and Opportunities
Roden, D. M., Altman, R. B., Benowitz, N. L., Flockhart, D. A., Giacomini, K. M., Johnson, J. A., Krauss, R. M., McLeod, H. L., Ratain, M. J., Relling, M. V., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00007 · Cited by 282
genotype status and effect of omeprazole on intragastric pH in humans
FURUTA, T., OHASHI, K., KOSUGE, K., ZHAO, X., TAKASHIMA, M., KIMURA, M., NISHIMOTO, M., HANAI, H., KANEKO, E., & ISHIZAKI, T. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70075-5 · Cited by 272
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males
Zhang, W., Yu, B.-N., He, Y.-J., Fan, L., Li, Q., Liu, Z.-Q., Wang, A., Liu, Y.-L., Tan, Z.-R., Fen-Jiang, et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.05.010 · Cited by 263
MacPhee, I. A. M., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L., & Holt, D. W. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00435.x · Cited by 258
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
Gage, B. F., & Lesko, L. J. (2008) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0104-y · Cited by 254
Wang, L., Zhang, D., Raghavan, N., Yao, M., Ma, L., Frost, C. A., Maxwell, B. D., Chen, S.-Y., He, K., Goosen, T. C., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029694 · Cited by 253
LIMA, J., THOMASON, D., MOHAMED, M., EBERLE, L., SELF, T., & JOHNSON, J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70071-8 · Cited by 250
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1
SPARREBOOM, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.003 · Cited by 241
Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Zhou, S.-F., Ming Di, Y., Chan, E., Du, Y.-M., Chow, V., Xue, C., Lai, X., Wang, J.-C., Li, C., Tian, M., et al. (2008) · Current Drug Metabolism · doi:10.2174/138920008786049302 · Cited by 211
Farlow, M. R., Lahiri, D. K., Poirier, J., Davignon, J., Schneider, L., & Hui, S. L. (1998) · Neurology · doi:10.1212/wnl.50.3.669 · Cited by 199
Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib
Stegmeier, F., Warmuth, M., Sellers, W. R., & Dorsch, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.297 · Cited by 192
Nebert, D. W., Zhang, G., & Vesell, E. S. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530801952864 · Cited by 181
The Acetylator Genes and Drug Response
Weber, W. W. (1987) · Cited by 176
Irinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein
de Jong, F. A., Scott-Horton, T. J., Kroetz, D. L., McLeod, H. L., Friberg, L. E., Mathijssen, R. H., Verweij, J., Marsh, S., & Sparreboom, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100019 · Cited by 171
The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day
Davidson, M. H., Stein, E. A., Dujovne, C. A., Hunninghake, D. B., Weiss, S. R., Knopp, R. H., Illingworth, D. R., Mitchel, Y. B., Melino, M. R., Zupkis, R. V., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00742-4 · Cited by 167
Digoxin pharmacokinetics and MDR1 genetic polymorphisms
Verstuyft, C., Schwab, M., Schaeffeler, E., Kerb, R., Brinkmann, U., Jaillon, P., Funck-Brentano, C., & Becquemont, L. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0567-5 · Cited by 166
SOME STATISTICAL DATA ON ATYPICAL CHOLINESTERASE OF HUMAN SERUM
KALOW, W., & GUNN, D. R. (1959) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1959.tb01467.x · Cited by 160
Use of Pharmaco-Metabonomics for Early Prediction of Acetaminophen-Induced Hepatotoxicity in Humans
Winnike, J., Li, Z., Wright, F. A., Macdonald, J. M., O’Connell, T. M., & Watkins, P. B. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.240 · Cited by 160
Tomlinson, B., Hu, M., Lee, V. W. Y., Lui, S. S. H., Chu, T. T. W., Poon, E. W. M., Ko, G. T. C., Baum, L., Tam, L., & Li, E. K. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.232 · Cited by 146
TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients
Pirmohamed, M., Lin, K., Chadwick, D. W., & Park, B. K. (2001) · Neurology · doi:10.1212/wnl.56.7.890 · Cited by 134
The Pharmocogenomics of Warfarin: Closing in on Personalized Medicine
Rettie, A. E. (2006) · Molecular Interventions · doi:10.1124/mi.6.4.8 · Cited by 132
Hagihara, K., Kazui, M., Kurihara, A., Yoshiike, M., Honda, K., Okazaki, O., Farid, N. A., & Ikeda, T. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028498 · Cited by 124
Limdi, N. A., & Veenstra, D. L. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.9.1084 · Cited by 124
Pharmacogenomics of Human UDP-Glucuronosyltransferases and Irinotecan Toxicity
Tukey, R. H., Strassburg, C. P., & Mackenzie, P. I. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.446 · Cited by 120
Pharmacogenomics of 4-Hydroxycoumarin Anticoagulants
Au, N. T., & Rettie, A. E. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530801952187 · Cited by 110
Pharmacogenomics of MRP Transporters (ABCC1-5) and BCRP (ABCG2)
Gradhand, U., & Kim, R. B. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530801952617 · Cited by 109
Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans
Zhang, D., He, K., Raghavan, N., Wang, L., Mitroka, J. G., Maxwell, B. D., Knabb, R. M., Frost, C. E., Schuster, A. E., Feng, H., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.025981 · Cited by 108
Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy
Jacobsen, P. K., Rossing, K., Rossing, P. R., Tarnow, L., Mallet, C., Poirier, O., Cambien, F., & Parving, H. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00847.x · Cited by 105
Schwab, M. G., Schaeffeler, E., Klotz, U. E., & Treiber, G. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.002 · Cited by 97
Voora, D., Koboldt, D. C., King, C. R., Lenzini, P. A., Eby, C. S., Porche-Sorbet, R., Deych, E., Crankshaw, M. W., Milligan, P. E., McLeod, H. L., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.291 · Cited by 93
Pharmacogenetic perspectives gained from twin and family studies
Vesell, E. S. (1989) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(89)90130-7 · Cited by 90
Kohno, M., Yokokawa, K., Minami, M., Kano, H., Yasunari, K., Hanehira, T., & Yoshikawa, J. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00067-4 · Cited by 78
Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Lin, J. H. (2007) · Current Drug Metabolism · doi:10.2174/138920007779816002 · Cited by 75
A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity
Kim, M., Huang, S. M., Meyer, U., Rahman, A., & Lesko, L. J. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008328098 · Cited by 73
Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster
Alfirevic, A., Mills, T., Harrington, P., Pinel, T., Sherwood, J. L., Jawaid, A., Smith, J. C., March, R. E., Barratt, B. J., Chadwick, D. W., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000189800.88596.7a · Cited by 65
Green, J., Banks, E., de González, A. B., Darby, S. C., Deo, H., & Newton, R. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1265 · Cited by 60
Miyazaki, M., Nakamura, K., Fujita, Y., Guengerich, F. P., Horiuchi, R., & Yamamoto, K. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021816 · Cited by 60
Lu, A. Y. H. (1998) · PubMed · Cited by 58
Self-citationOrigins of Individual Variability in P4501A Induction
Ma, Q., & Lu, A. Y. H. (2003) · Chemical Research in Toxicology · doi:10.1021/tx0200919 · Cited by 46
Self-citationCan personalized drug therapy be achieved? A closer look at pharmaco-metabonomics.
Nebert, D., & Vesell, E. (2006) · TIPS - Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.09.008 · Cited by 45
The Challenges of Dealing with Promiscuous Drug-Metabolizing Enzymes, Receptors and Transporters
Ma, Q., & Lu, A. Y. H. (2008) · Current Drug Metabolism · doi:10.2174/138920008784746337 · Cited by 42
Self-citationGenetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants
Schwarz, U. I., & Stein, C. M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.04.008 · Cited by 33
Cited by
How informative is the mouse for human gut microbiota research?
Nguyen, T. L. A., Vieira-Silva, S., Liston, A., & Raes, J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017400 · Cited by 1,334
“Vereecke et al. recently developed a mouse model prone to spontaneous colitis (Vereecke et al., 2014), while studying A20 – an inhibitor of both NF-κB and apoptotic signaling that has previously been associated with susceptibility to IBD in humans (Catrysse et al., 2014; Ma and Malynn, 2012).”
Background3D printing in pharmaceutics: A new tool for designing customized drug delivery systems
Goole, J., & Amighi, K. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.12.071 · Cited by 660
Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
Zolotovskaia, M. A., Sorokin, M. I., Emelianova, A. A., Borisov, N. M., Kuzmin, D. V., Borger, P., Garazha, A. V., & Buzdin, A. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00001 · Cited by 531
Malaria medicines: a glass half full?
Wells, T. N. C., van Huijsduijnen, R. H., & Van Voorhis, W. C. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4573 · Cited by 430
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z., Zhou, J., & Chen, S.-Q. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 371
Metadata
- Authors
- Ma, Q., & Lu, A. Y. H.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 63
- Issue
- 2
- Pages
- 437-459
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2124575784
- Cited by
- 464
- References
- 105
- FWCI
- 38.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.